**Ustekinumab**, sold under the brand name Stelara is a monoclonal antibody medication developed by [[Janssen Pharmaceuticals]], for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23. Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to more traditional treatments. It was found not effective for multiple sclerosis. It is administered either by intravenous infusion or subcutaneous injection. The antibody targets a subunit of human interleukin 12 and interleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. The FDA approved ustekinumab in September 2016, for the treatment of Crohn's disease. In October 2019, the FDA approved the use of ustekinumab for adults with moderately to severely active ulcerative colitis. Source: [Wikipedia](https://en.wikipedia.org/wiki/Ustekinumab)